Metabolic determinants of cancer cell sensitivity to glucose limitation and biguanides

Birsoy K., POSSEMATO R., LORBEER F. K., BAYRAKTAR E. C., THIRU P., Yucel B., ...More

NATURE, vol.508, no.7494, pp.108-125, 2014 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 508 Issue: 7494
  • Publication Date: 2014
  • Doi Number: 10.1038/nature13110
  • Journal Name: NATURE
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.108-125
  • Karadeniz Technical University Affiliated: Yes


As the concentrations of highly consumed nutrients, particularly glucose, are generally lower in tumours than in normal tissues(1,2), cancer cells must adapt their metabolism to the tumour microenvironment. Abetter understanding of these adaptations might reveal cancer cell liabilities that can be exploited for therapeutic benefit. Here we developed a continuous-flow culture apparatus (Nutrostat) for maintaining proliferating cells in low-nutrient media for long periods of time, and used it to undertake competitive proliferation assays on a pooled collection of barcoded cancer cell lines cultured in low-glucose conditions. Sensitivity to low glucose varies amongst cell lines, and an RNA interference (RNAi) screen pinpointed mitochondrial oxidative phosphorylation (OXPHOS) as the major pathway required for optimal proliferation in low glucose. We found that cell lines most sensitive to low glucose are defective in the OXPHOS upregulation that is normally caused by glucose limitation as a result of either mitochondrial DNA (mtDNA) mutations in complex I genes or impaired glucose utilization. These defects predict sensitivity to biguanides, antidiabetic drugs that inhibit OXPHOS3,4, when cancer cells are grown in low glucose or as tumour xenografts. Notably, the biguanide sensitivity of cancer cells with mtDNA mutations was reversed by ectopic expression of yeast NDI1, a ubiquinone oxidoreductase that allows bypass of complex I function(5). Thus, we conclude that mtDNA mutations and impaired glucose utilization are potential biomarkers for identifying tumours with increased sensitivity to OXPHOS inhibitors.